Teva Pharmaceutical Industries Ltd (TEVA.TA)

TEVA.TA on Tel Aviv Stock Exchange

21,870.00
18 Dec 2014
Price Change (% chg)

200.00₪ (+0.92%)
Prev Close
21,670.00₪
Open
21,820.00₪
Day's High
21,870.00₪
Day's Low
21,820.00₪
Volume
74,022
Avg. Vol
501,659
52-wk High
23,070.00₪
52-wk Low
13,560.00₪

TEVA.TA

Chart for TEVA.TA

About

Teva Pharmaceutical Industries Ltd (Teva) is an Israel-based pharmaceutical and drug company. It develops, produces and markets generic drugs in all treatment categories. The Company has a pharmaceutical business, whose principal products include Copaxone and Azilect. Teva’s active pharmaceutical ingredient (API) business... (more)

Overall

Beta: 0.67
Market Cap (Mil.): ₪208,917.70
Shares Outstanding (Mil.): 956.39
Dividend: 121.00
Yield (%): 2.20

Financials

  TEVA.TA Industry Sector
P/E (TTM): 17.44 37.01 37.62
EPS (TTM): 12.53 -- --
ROI: 7.79 18.05 17.39
ROE: 11.96 18.84 18.30
Search Stocks

Teva Pharm sees 2015 revenue lower than forecast

TEL AVIV - Teva Pharmaceutical Industries forecast 2015 revenue below analysts' expectations, due to adverse foreign exchange moves and generic competition for its best-selling multiple sclerosis treatment Copaxone.

11 Dec 2014

Teva Pharm sees 2015 revenue lower than forecast

TEL AVIV - Teva Pharmaceutical Industries forecast 2015 revenue below analysts' expectations, due to adverse foreign exchange moves and generic competition for its best-selling multiple sclerosis treatment Copaxone.

11 Dec 2014

UPDATE 1-Teva Pharm sees 2015 revenue lower than forecast

TEL AVIV, Dec 11 - Teva Pharmaceutical Industries forecast 2015 revenue below analysts' expectations, due to adverse foreign exchange moves and generic competition for its best-selling multiple sclerosis treatment Copaxone.

11 Dec 2014

Teva Pharm sees lower than forecast 2015 revenue

TEL AVIV, Dec 11 - Teva Pharmaceutical Industries , the world's biggest generic drugmaker, forecast 2015 revenue below analysts' expectations and assumes its best-selling multiple sclerosis treatment will face competition in September.

11 Dec 2014

BRIEF-Active Biotech and Teva expand Laquinimod clinical development program

* Teva and Active Biotech announce expansion of Laquinimod clinical development program with new trial in primary progressive multiple sclerosis and first patient screened in Huntington's Disease trial Source text for Eikon: Further company coverage:

04 Nov 2014

Teva raises 2014 profit forecast after strong third quarter

TEL AVIV - Teva Pharmaceutical Industries reported stronger than expected third-quarter profits due to improved profitability for its generic medicines, and was hopeful of keeping patent protection for best-selling drug Copaxone.

30 Oct 2014

UPDATE 2-Teva raises 2014 profit forecast after strong third quarter

* Raises 2014 EPS outlook to $5.00-$5.10 from pvs $4.90-$5.10

30 Oct 2014

Teva optimistic U.S. top court to rule in favor of MS drug patent

TEL AVIV - Teva Pharmaceutical Industries is optimistic the U.S. Supreme Court will decide in its favor regarding patent protection for Copaxone, its multiple sclerosis treatment, Chief Executive Erez Vigodman said on Thursday.

30 Oct 2014

Teva optimistic U.S. top court to rule in favour of MS drug patent

TEL AVIV, Oct 30 - Teva Pharmaceutical Industries is optimistic the U.S. Supreme Court will decide in its favour regarding patent protection for Copaxone, its multiple sclerosis treatment, Chief Executive Erez Vigodman said on Thursday.

30 Oct 2014

Teva Pharm Q3 profit beats estimates, raises 2014 EPS forecast

TEL AVIV, Oct 30 - Teva Pharmaceutical Industries reported quarterly profit that beat analysts' estimates on Thursday and raised its earnings forecast for the full year.

30 Oct 2014

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: Stock Traders Daily
$20.00
Provider: New Constructs, LLC
$25.00
Provider: MacroRisk Analytics/EconomicInvestor
$25.00
Provider: GlobalData
$125.00
Provider: S&P Capital IQ – STARS Reports
$127.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks